Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Perrigo Company has filed a New Drug Application (NDA) with the US FDA for testosterone gel 1.0% and has notified Abbott Products, the owner of the Reference Listed Drug.
Subscribe to our email newsletter
Abbott filed suit against Perrigo on 31 October 2011 over patent infringement.
Androgel 1.0% (testosterone gel 1.0%) is used in the treatment of adult males who have low or no testosterone.
Perrigo chairman and CEO Joseph C Papa said the move implies the company’s investment in new products and expansion of their extended topicals pipeline.
"As always, Perrigo is committed to making quality healthcare more affordable for our customers," Papa added.